Ingenia's Same-Day Filings: $5M MK-8748 Milestone From Merck's EyeBio, and an FDA IND for IGT-303
Korea Supply Chain Brief · September 28, 2026
Ingenia Therapeutics (KOSDAQ: 950260) filed two disclosures on the same day: a US$5 million (about KRW 6.8 billion) milestone payment tied to MK-8748, its eye-disease antibody licensed to a Merck subsidiary, and a U.S. FDA application to start human trials of a second drug, IGT-303, for chronic kidney disease. Here is what each filing says and how they connect.
| Company | Role | Evidence |
|---|---|---|
| Ingenia Therapeutics KOSDAQ: 950260 | Originator of MK-8748 and IGT-303 | Filings (KRX/DART, Sep 28, 2026) |
| EyeBio (Eyebiotech Limited) | Licensee of MK-8748 since 2022; now a Merck subsidiary | Filing |
| Merck & Co. (MSD) NYSE: MRK | Acquired EyeBio in 2024; runs the MK-8748 Phase 3 program | Reported (The Bio, Apr 6, 2026) |
Filing 1: US$5M milestone for MK-8748
- Trigger: EyeBio started a global Phase 3 trial of MK-8748 in diabetic macular edema (DME).
- Amount: US$5,000,000, about KRW 6.8 billion.
- Origin: the 2022 license agreement under which Ingenia transferred MK-8748 to EyeBio (Newsis reports the license year as 2022; an earlier filing dated it October 31, 2022).
MK-8748 is a bispecific antibody: it blocks VEGF, the signal behind leaky blood vessels in the eye, and activates Tie2, a separate pathway that stabilizes vessels. Standard treatments such as aflibercept only do the first part. Merck, which bought EyeBio in 2024, is running four Phase 3 trials in wet age-related macular degeneration and diabetic macular edema covering roughly 4,000 patients, according to Financial Post (Sep 18, 2026).
Filing 2: IND filed for IGT-303 in the U.S.
On the same day, Ingenia disclosed it submitted an Investigational New Drug (IND) application to the FDA for IGT-303, a chronic kidney disease (CKD) candidate, to start a Phase 1/2a trial in the United States.
- Design: multi-center, randomized, double-blind, placebo-controlled, in healthy volunteers and CKD patients.
- Two parts: Part A is a single ascending dose (SAD) study across 6 dose groups; Part B is a multiple ascending dose (MAD) study across 3 groups, testing both intravenous and subcutaneous administration.
- Enrollment target: 94 subjects.
- Duration: about 6 months from approval, though Ingenia said the total timeline could shift depending on enrollment.
- Context: the company says this U.S. trial uses the same design as a Phase 2a study already running in Australia, New Zealand and South Korea.
An Ingenia representative told Newsis the company is in licensing talks with multiple global big pharma companies over IGT-303, and entered the U.S. trial "preemptively" to raise the odds of a license deal and move late-stage development forward, planning to apply know-how from its EyeBio collaboration on FDA approval and clinical development.
How the two filings connect
Both disclosures point to the same playbook: Ingenia develops a drug in-house, then looks to license it to a larger partner once clinical data and, increasingly, direct U.S. regulatory contact de-risk the asset. MK-8748 shows what that path can look like years later — a licensee-turned-Merck-subsidiary running large global trials and paying milestones. IGT-303 is earlier: no license has been announced, and the company's own comment frames the IND filing as a step taken specifically to make a future license more attractive.
What is not disclosed
- The total value of the 2022 MK-8748 license, or how much Ingenia has received under it to date.
- Which "global big pharma" companies are in talks over IGT-303, or any terms.
- Results from the ongoing Australia/New Zealand/Korea Phase 2a trial of IGT-303.
Quick FAQ
What is the MK-8748 milestone for?
EyeBio, a Merck subsidiary, started a global Phase 3 trial of MK-8748 in diabetic macular edema, triggering a US$5 million payment to Ingenia under their 2022 license.
What is IGT-303?
An Ingenia drug candidate for chronic kidney disease. The company just filed to begin a U.S. Phase 1/2a trial, alongside an already-running Phase 2a trial in Australia, New Zealand and Korea.
Has IGT-303 been licensed to anyone?
No license has been disclosed. Ingenia says it is in talks with multiple large pharmaceutical companies.
Source (Korean): 뉴시스 (Newsis), Sep 28, 2026, reporter Lee So-heon. https://www.newsis.com/view/NISX20260928_0003805953 ; background on MK-8748 and the Merck/EyeBio deal from The Bio (더바이오), Apr 6, 2026, and Financial Post (파이냸셜포스트), Sep 18, 2026.
This brief is our own summary and analysis, not a translation. It is not investment advice. See our Disclaimer and evidence labels.
Stock Anatomy · Last checked: September 28, 2026